Evidence map›Paper›PMID 39499486›Full record

Trial reportClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2025

Degradation fragments of Tau and type IV collagen as serum biomarkers in patients with recurrent glioblastoma treated with nivolumab and bevacizumab.

Christina Jensen, Simone Maarup, Hans Skovgaard Poulsen, Benedikte Hasselbalch, Morten Karsdal, Inge Marie Svane, Ulrik Lassen, Nicholas Willumsen

Registry-linked trialAbstract readClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03890952 (A Phase II Open Label, Two-armed Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03890952 phase2completednot on this map

A Phase II Open Label, Two-armed Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma

TypeinterventionalSponsorUlrik LassenRan2018 to 2024Enrolled40ConditionsRecurrent Adult Brain TumorArmsNivolumab, Bevacizumab
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. The Duality of Collagens in Metastases of Solid Tumors.International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Christina JensenNordic Bioscience A/S, Herlev, Denmark.
Simone MaarupThe DCCC Brain Tumor Center, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Hans Skovgaard PoulsenThe DCCC Brain Tumor Center, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Benedikte HasselbalchThe DCCC Brain Tumor Center, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Morten KarsdalNordic Bioscience A/S, Herlev, Denmark.
Inge Marie SvaneNational Center for Cancer Immune Therapy, CCIT-DK, Copenhagen University Hospital, Herlev, Denmark.
Ulrik LassenThe DCCC Brain Tumor Center, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Nicholas WillumsenNordic Bioscience A/S, Herlev, Denmark. nwi@nordicbio.com.ORCID http://orcid.org/0000-0002-5207-5173

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThere is an unmet need for new treatment options and biomarkers for patients with glioblastoma (GBM). Here we investigated three non-invasive biomarkers: type VI collagen degraded by granzyme B (C4G) and matrix metalloproteases (C4M), respectively, and ADAM10-degraded Tau (Tau-A).

methodsBiomarker levels in pre- and on-treatment serum samples from patients with recurrent GBM (n = 39) treated with nivolumab and bevacizumab (NCT03890952) were compared to healthy levels (n = 22) and associated with overall survival (OS) outcome (median cutpoint). Longitudinal changes in biomarkers were investigated by a Mixed-effects analysis.

resultsTau-A (p < 0.0001) and C4G (p = 0.005), but not C4M (p = 0.106), were increased in patients. High Tau-A and C4G associated with improved OS (Tau-A: HR = 0.41, 95%CI = 0.20-0.86, C4G: HR = 0.47, 95%CI = 0.24-0.94). Only C4G increased with treatment (p = 0.024-0.005).

conclusionsTau-A and C4G are elevated in serum from patients with recurrent GBM and prognostic for OS. If validated, these biomarkers could be applied to clinical trials.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBrain NeoplasmsCollagen Type IVGlioblastomaNeoplasm Recurrence, Localtau ProteinsADAM10 ProteinAdultAgedAmyloid Precursor Protein SecretasesBevacizumabFemaleGranzymesHumansMaleADAM10 ProteinADAM10 protein, humanAmyloid Precursor Protein SecretasesBevacizumabBiomarkers, TumorCollagen Type IVGranzymesGZMB protein, humanMAPT protein, humanMembrane ProteinsNivolumabtau ProteinsBiomarkersCollagenGlioblastomaTauTumor microenvironment

Identifiers

PMID39499486

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.